NCT06708936View on ClinicalTrials.gov

KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
BIOLOGICAL

KSD-201

Patients will receive approximately 5x10\^6 cells/dose DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.

Trial Locations (1)

430000

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Kousai Bio Co., Ltd.

OTHER